TS-142 5 mg

DRUG3 trials

Sponsors

Taisho Pharmaceutical Co., Ltd.

Conditions

Patients with InsomniaPatients with Mild or Moderate Hepatic Impairment

Phase 1

A Pharmacokinetic Study of TS-142 in Patients with Hepatic Impairment

CompletedNCT05624944

Taisho Pharmaceutical Co., Ltd.Patients with Mild or Moderate Hepatic Impairment

Start: 2022-12-26End: 2023-12-05Updated: 2025-02-28

Phase 3

Phase III Study of TS-142 in Patients with Insomnia

CompletedNCT05453136

Taisho Pharmaceutical Co., Ltd.Patients with Insomnia

Start: 2022-08-30End: 2023-12-05Updated: 2025-02-28

Long-Term Study of TS-142 in Patients with Insomnia

CompletedNCT05461352

Taisho Pharmaceutical Co., Ltd.Patients with Insomnia

Start: 2022-10-11End: 2024-03-07Updated: 2025-02-28

Related Papers

Efficacy and safety of vornorexant in Japanese patients with insomnia: a randomized, placebo-controlled phase 3 pivotal study

SLEEP2025-09-262 citations